American Biotech Labs has announced that it has obtained clearance by the FDA to market its ASAP Antibacterial Silver Wound Dressing Gel as a prescription 510(k) medical device throughout the United States. The FDA 510(k) medical device clearance enables ABL to market its ASAP Antibacterial Silver Gel “for use in the management of 1st and 2nd degree burns, stasis ulcers, pressure ulcers, diabetic ulcers, lacerations, abrasions, skin tears and surgical incision sites.

Fresenius Medical Care has launched a new therapy program for peritoneal dialysis (PD). ‘P3′, the first comprehensive PD care concept of its kind. In contrast to the mere provision of individual products and services, ‘P3′ for the first time provides PD therapy as an integrated care program, incorporating all aspects of treatment, from the PD machine, or “cycler”, and related equipment to special software and services for the monitoring of treatment safety and quality

APP Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. Chlorothiazide Sodium for Injection, USP is therapeutically equivalent to the reference-listed drug Diuril®, which is marketed by Lundbeck Pharmaceuticals. Chlorothiazide is a diuretic used to treat high blood pressure, and fluid retention in people with congestive heart failure, cirrhosis of the liver and kidney disorders.

3M Health Care the innovative technology company haslaunched the first Antimicrobial Tegaderm CHG IV Transparent Securement Dressing at the 2009 Patient Safety Congress, Abu Dhabi. The dressing integrates the powerful antimicrobial action of Chlorhexidine Gluconate (CHG) with the high performance of a Tegaderm dressing, and has been designed to reduce skin flora – the most common cause of catheter-related bloodstream infection (CR-BSI), which can prolong hospital stays by an average of 20 days.